Cargando…

Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.

During recent years N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been developed as targetable drug carriers. These soluble synthetic polymers are internalized by cells by pinocytosis and they can be tailor-made to include peptidyl side-chains degradable intracellularly by specific lysoso...

Descripción completa

Detalles Bibliográficos
Autores principales: Duncan, R., Kopecková-Rejmanová, P., Strohalm, J., Hume, I., Cable, H. C., Pohl, J., Lloyd, J. B., Kopecek, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002078/
https://www.ncbi.nlm.nih.gov/pubmed/3468994
_version_ 1782135694166065152
author Duncan, R.
Kopecková-Rejmanová, P.
Strohalm, J.
Hume, I.
Cable, H. C.
Pohl, J.
Lloyd, J. B.
Kopecek, J.
author_facet Duncan, R.
Kopecková-Rejmanová, P.
Strohalm, J.
Hume, I.
Cable, H. C.
Pohl, J.
Lloyd, J. B.
Kopecek, J.
author_sort Duncan, R.
collection PubMed
description During recent years N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been developed as targetable drug carriers. These soluble synthetic polymers are internalized by cells by pinocytosis and they can be tailor-made to include peptidyl side-chains degradable intracellularly by specific lysosomal enzymes. Thus they provide the opportunity fo achieve controlled intracellular delivery of anticancer agents. The anthracycline antibiotic daunomycin, and protein synthesis inhibitor puromycin, were bound to HPMA copolymers via several different peptide side-chains, including Gly-Gly, Gly-Phe-Leu-Gly and Gly-Phe-Phe-Leu. Incubation of polymer-drug conjugates with isolated lysosomal enzymes (either a mixture of rat liver lysosomal enzymes or purified thiol-dependent lysosomal proteinases, cathepsins L and B) showed that significant release of drug occurred over 20 h, more than 20% of daunomycin and more than 80% of puromycin being liberated. To test their pharmacological activity conjugates were incubated with either the mouse leukaemia L1210, or the human lymphoblastoid leukaemia CCRF in vitro. The conjugates tested were all less effective than free daunomycin, but they showed differential toxicity against L1210 depending on the aminoacid sequence of their drug-polymer linkage. Inclusion of fucosylamine-terminating side-chains into the HPMA copolymer structure increased the affinity of conjugates for the L1210 cell membrane and resulted in increased toxicity. In contrast HPMA-daunomycin conjugates with or without fucosylamine affected CCRF cells equally, but this cell line was more sensitive than the mouse leukaemia to both free and polymer-bound daunomycin. Incubation of L1210 cells in polymer-bound daunomycin for 72 h, followed by plating cells out in low density in drug-free medium, showed that a concentration of polymer-bound drug (184 micrograms ml-1) could be selected to achieve a cytotoxic effect.
format Text
id pubmed-2002078
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20020782009-09-10 Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Duncan, R. Kopecková-Rejmanová, P. Strohalm, J. Hume, I. Cable, H. C. Pohl, J. Lloyd, J. B. Kopecek, J. Br J Cancer Research Article During recent years N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been developed as targetable drug carriers. These soluble synthetic polymers are internalized by cells by pinocytosis and they can be tailor-made to include peptidyl side-chains degradable intracellularly by specific lysosomal enzymes. Thus they provide the opportunity fo achieve controlled intracellular delivery of anticancer agents. The anthracycline antibiotic daunomycin, and protein synthesis inhibitor puromycin, were bound to HPMA copolymers via several different peptide side-chains, including Gly-Gly, Gly-Phe-Leu-Gly and Gly-Phe-Phe-Leu. Incubation of polymer-drug conjugates with isolated lysosomal enzymes (either a mixture of rat liver lysosomal enzymes or purified thiol-dependent lysosomal proteinases, cathepsins L and B) showed that significant release of drug occurred over 20 h, more than 20% of daunomycin and more than 80% of puromycin being liberated. To test their pharmacological activity conjugates were incubated with either the mouse leukaemia L1210, or the human lymphoblastoid leukaemia CCRF in vitro. The conjugates tested were all less effective than free daunomycin, but they showed differential toxicity against L1210 depending on the aminoacid sequence of their drug-polymer linkage. Inclusion of fucosylamine-terminating side-chains into the HPMA copolymer structure increased the affinity of conjugates for the L1210 cell membrane and resulted in increased toxicity. In contrast HPMA-daunomycin conjugates with or without fucosylamine affected CCRF cells equally, but this cell line was more sensitive than the mouse leukaemia to both free and polymer-bound daunomycin. Incubation of L1210 cells in polymer-bound daunomycin for 72 h, followed by plating cells out in low density in drug-free medium, showed that a concentration of polymer-bound drug (184 micrograms ml-1) could be selected to achieve a cytotoxic effect. Nature Publishing Group 1987-02 /pmc/articles/PMC2002078/ /pubmed/3468994 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Duncan, R.
Kopecková-Rejmanová, P.
Strohalm, J.
Hume, I.
Cable, H. C.
Pohl, J.
Lloyd, J. B.
Kopecek, J.
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title_full Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title_fullStr Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title_full_unstemmed Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title_short Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.
title_sort anticancer agents coupled to n-(2-hydroxypropyl)methacrylamide copolymers. i. evaluation of daunomycin and puromycin conjugates in vitro.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002078/
https://www.ncbi.nlm.nih.gov/pubmed/3468994
work_keys_str_mv AT duncanr anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT kopeckovarejmanovap anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT strohalmj anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT humei anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT cablehc anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT pohlj anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT lloydjb anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro
AT kopecekj anticanceragentscoupledton2hydroxypropylmethacrylamidecopolymersievaluationofdaunomycinandpuromycinconjugatesinvitro